Selected article for: "high mortality and influenza pandemic"
Author: Choreño-Parra, José Alberto; Jiménez-Álvarez, Luis Armando; Ramírez-Martínez, Gustavo; Cruz-Lagunas, Alfredo; Thapa, Mahima; Fernández-López, Luis Alejandro; Carnalla-Cortés, Martha; Choreño-Parra, Eduardo M; Mena-Hernández, Lourdes; Sandoval-Vega, Montserrat; Hernández-Montiel, Erika Mariana; Hernández-García, Diana Lizzeth; Ramírez-Noyola, Jazmín Ariadna; Reyes-López, Cynthia Estefania; Domínguez-Faure, Andrea; Zamudio-López, Guillermo Yamil; Márquez-García, Eduardo; Moncada-Morales, Angélica; Mendoza-Milla, Criselda; Cervántes-Rosete, Diana; Muñoz-Torrico, Marcela; Luna-Rivero, Cesar; García-Latorre, Ethel A; Guadarrama-Ortíz, Parménides; Ávila-Moreno, Federico; Domínguez-Cherit, Guillermo; Rodríguez-Reyna, Tatiana Sofía; Mudd, Philip A; Hernández-Cárdenas, Carmen Margarita; Khader, Shabaana A; Zúñiga, Joaquín
Title: Expression of Surfactant protein D (SP-D) distinguishes severe pandemic influenza A(H1N1) from COVID-19
  • Cord-id: rlonudx9
  • Document date: 2021_3_1
    • ID: rlonudx9
    Snippet: The differentiation of influenza and COVID-19 could constitute a diagnostic challenge during the ongoing winter due to their clinical similitude. Thus, novel biomarkers that enable distinguishing both diseases are required. Here, we evaluated whether the surfactant protein D (SP-D), a collectin produced at the alveolar epithelium with known immune properties, was useful to differentiate pandemic influenza A(H1N1) from COVID-19 in critically ill patients. Our results revealed high serum SP-D leve
    Document: The differentiation of influenza and COVID-19 could constitute a diagnostic challenge during the ongoing winter due to their clinical similitude. Thus, novel biomarkers that enable distinguishing both diseases are required. Here, we evaluated whether the surfactant protein D (SP-D), a collectin produced at the alveolar epithelium with known immune properties, was useful to differentiate pandemic influenza A(H1N1) from COVID-19 in critically ill patients. Our results revealed high serum SP-D levels in severe pandemic influenza but not COVID-19 patients. This finding was validated in a separate cohort of mechanically ventilated COVID-19 patients who also showed low plasma SP-D levels. However, plasma SP-D levels did not distinguish seasonal influenza from COVID-19 in mild-to-moderate disease. Finally, we found that high serum SP-D levels were associated with mortality and renal failure among severe pandemic influenza cases. Thus, our studies have identified SP-D as a unique biomarker expressed during severe pandemic influenza but not COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acute physiology chronic health evaluation ii and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute physiology chronic health evaluation ii and logistic regression model: 1, 2
    • acute physiology chronic health evaluation ii and louis jewish hospital: 1
    • acute physiology chronic health evaluation ii and lung injury: 1, 2, 3
    • admission sequential sofa organ failure assessment and logistic regression: 1, 2, 3
    • admission sequential sofa organ failure assessment and logistic regression model: 1
    • admission sequential sofa organ failure assessment and lopinavir ritonavir: 1
    • logistic regression and longitudinal change: 1, 2, 3
    • logistic regression and longitudinal increase: 1
    • logistic regression and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
    • logistic regression and lung condition: 1
    • logistic regression and lung damage: 1, 2, 3, 4, 5, 6, 7, 8
    • logistic regression and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • logistic regression model and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
    • logistic regression model and lung damage: 1, 2
    • logistic regression model and lung injury: 1, 2, 3
    • lopinavir ritonavir and lung condition: 1
    • lopinavir ritonavir and lung damage: 1, 2, 3, 4, 5, 6
    • lopinavir ritonavir and lung disorder: 1